Laurence Albiges, MD, PhD As different subtypes of non–clear cell renal cell carcinoma (non–ccRCC) continue to be better defined, ongoing research aims to develop optimal treatment...
In a study of over 500 treatment-naïve men with at least one of three major risk factors for prostate cancer, 43 percent of those with all...
Shadmehr Demehri, MD, PhD The statin pitavastatin (Livalo) could potentially inhibit the production of IL-33, which often contributes to the development of cancer via chronic inflammation,...
In an interview with OncLive®, Sanjal Desai, MD, discussed the feasibility of venetoclax (Venclexta) rechallenge in patients with chronic lymphocytic leukemia (CLL) who progressed on prior...